These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 17643100

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms.
    Takahashi K, Patel KP, Kantarjian H, Luthra R, Pierce S, Cortes J, Verstovsek S.
    Blood; 2013 Nov 28; 122(23):3784-6. PubMed ID: 24068492
    [Abstract] [Full Text] [Related]

  • 3. Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis.
    Konoplev S, Hsieh PP, Chang CC, Medeiros LJ, Lin P.
    Hum Pathol; 2007 Dec 28; 38(12):1760-3. PubMed ID: 17707884
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Megakaryopoiesis and platelet function in polycythemia vera and essential thrombocythemia patients with JAK2 V617F mutation.
    Hattori N, Fukuchi K, Nakashima H, Maeda T, Adachi D, Saito B, Yanagisawa K, Matsuda I, Nakamaki T, Gomi K, Tomoyasu S.
    Int J Hematol; 2008 Sep 28; 88(2):181-188. PubMed ID: 18612778
    [Abstract] [Full Text] [Related]

  • 6. JAK2 V617F patients with essential thrombocythemia present with clinical features of polycythemia vera.
    Zhang S, Qiu H, Fischer BS, Li W, Duan L, Sun X, Xu W, Li J.
    Leuk Lymphoma; 2008 Apr 28; 49(4):696-9. PubMed ID: 18398736
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL, Marton E, Plander M.
    Orv Hetil; 2011 Nov 06; 152(45):1795-803. PubMed ID: 22011365
    [Abstract] [Full Text] [Related]

  • 9. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
    Hussein K, Brakensiek K, Buesche G, Buhr T, Wiese B, Kreipe H, Bock O.
    Ann Hematol; 2007 Apr 06; 86(4):245-53. PubMed ID: 17262192
    [Abstract] [Full Text] [Related]

  • 10. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N, Stacher E, Regitnig P, Zinke-Cerwenka W, Hojas S, Hubmann E, Porwit A, Bjorkholm M, Hoefler G, Beham-Schmid C.
    Arch Pathol Lab Med; 2014 Sep 06; 138(9):1203-9. PubMed ID: 25171702
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Transcription factor Fli-1 expression by bone marrow cells in chronic myeloproliferative disorders is independent of an underlying JAK2 (V617F) mutation.
    Bock O, Hussein K, Neusch M, Schlué J, Wiese B, Kreipe H.
    Eur J Haematol; 2006 Dec 06; 77(6):463-70. PubMed ID: 16930139
    [Abstract] [Full Text] [Related]

  • 13. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
    Hussein K, Bock O, Kreipe H.
    Pathobiology; 2007 Dec 06; 74(2):72-80. PubMed ID: 17587878
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.
    Toyama K, Karasawa M, Yamane A, Irisawa H, Yokohama A, Saitoh T, Handa H, Matsushima T, Sawamura M, Miyawaki S, Murakami H, Nojima Y, Tsukamoto N.
    Br J Haematol; 2007 Oct 06; 139(1):64-9. PubMed ID: 17854308
    [Abstract] [Full Text] [Related]

  • 17. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.
    Soderquist CR, Ewalt MD, Czuchlewski DR, Geyer JT, Rogers HJ, Hsi ED, Wang SA, Bueso-Ramos CE, Orazi A, Arber DA, Hexner EO, Babushok DV, Bagg A.
    Mod Pathol; 2018 May 06; 31(5):690-704. PubMed ID: 29327708
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.